TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04844892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lungpacer PROTECT Diaphragm Pacing Therapy
Description: PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
Study: NCT05667584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypotension prediction index derived from non-invasive arterial pressure waveforms
Description: The Hypotension Prediction Index (HPI) is an algorithm based on the complex analysis of features in high-fidelity arterial pressure waveform recordings developed to observe subtle signs that could predict the onset of hypotension in surgical and intensive care unit patients. HPI is a unitless number that ranges from 1 to 100, and as the number increases, the likelihood of a hypotensive event (MAP \<65 mm Hg for more than 1 minute) occurring in the near future increases. In a validation study on HPI conducted in patients under general anesthesia, the algorithm, at its optimal value, predicted hypotension with both sensitivity and specificity of 86% 5 minutes before the event. Measurement of the arterial pressure waveforms using a finger cuff (ClearSight) is well established.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive arterial pressure waveforms
Description: ClearSight is a non-invasive hemodynamic monitoring device using digital-cuff and volume-clamp technology to obtain a continuous arterial blood pressure waveform. Continuous finger blood pressure measurement is established by wrapping the cuff around the middle phalanx of a finger. The area under the waveform curve is analyzed using a unique algorithm that serves to calculate the arterial blood pressure, stroke volume (SV) and CO.
Study: NCT06447935

Intervention type: OTHER
Intervention: No intervention
Description: not applicable - no intervention required
Study: NCT06379672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resonance breathing
Description: Resonant breathing was used on the subjects, using nasal inhalation and oral exhalation, for a total of 12 weeks.
Study: NCT05857215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amilo-5MER
Description: amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amilo-5MER
Description: amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amilo-5MER
Description: amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amilo-5MER
Description: amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amilo-5MER
Description: amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
Study: NCT06064552

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sugar
Description: High and low risk women will undergo measuring fasting blood sugar after fasting 6-8hours with good hydration. then measuring blood sugar 1hrs and 2hrs postprandial. for patient with high results (FBS\>95mg/dl, 1hr postprandial\>126mg/dl, 2hrs postprandial \>140mg/dl) should do HA1C if \>5.6 consider it diabetic and dealing with whom positive as regard lifestyle management like diet and exercise 150 min. per week and whom not well controlled will be enrolled in pharmacological regimen as metformin.~For whom measures normal will be tested by the same method at 20- 24 wks of gestation

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sugar
Description: High and low risk women will undergo measuring fasting blood sugar after fasting 6-8hours with good hydration. then measuring blood sugar 1hrs and 2hrs postprandial. for patient with high results (FBS\>95mg/dl, 1hr postprandial\>126mg/dl, 2hrs postprandial \>140mg/dl) should do HA1C if \>5.6 consider it diabetic and dealing with whom positive as regard lifestyle management like diet and exercise 150 min. per week and whom not well controlled will be enrolled in pharmacological regimen as metformin.~For whom measures normal will be tested by the same method at 20- 24 wks of gestation
Study: NCT06025942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purrble intervention
Description: When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to young people in emotional moments when they would attempt to utilise emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in young peoples' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2.~* see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)
Study: NCT05315115

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Care
Description: A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical therapy intervention
Description: The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Description: The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
Study: NCT05368259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGBS
Description: The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
Study: NCT06381076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal curcumin
Description: participants will consume the product ad libitum for the 24 treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Food colorant
Description: participants will consume the product ad libitum for the 24 treatments as a placebo.
Study: NCT06325657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF vaccine
Description: RSVpreF vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebp
Description: Placebo
Study: NCT06169319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Biologic: Intrafascial injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Biologic: Intrafascial injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intrafascial injection
Study: NCT06029283

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary nitrate
Description: dietary nitrate in a chewing gum delivery vehicle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chewing gum
Description: placebo chewing gum
Study: NCT04074096

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotaxic radiosurgery (SRS)
Description: For patients randomised to arm B only: Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases \>5 mm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib Oral Tablet
Description: All patients: binimetinib 45 mg PO BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib Oral Tablet
Description: All patients: binimetinib 45 mg PO BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib Oral Capsule
Description: All patients: encorafenib 450 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib Oral Capsule
Description: All patients: encorafenib 450 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All patients: pembrolizumab 200 mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All patients: pembrolizumab 200 mg IV Q3W
Study: NCT05605925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/lumefantrine
Description: 4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: 4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: IVN 600 mcg/kg/day for 3 days
Study: NCT05490381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodixanol
Description: Given via injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiogram
Description: Undergo diagnostic cerebral angiogram

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Embolization
Description: Undergo tumor vessel embolization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyvinyl Alcohol
Description: Given via catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethiodized Oil
Description: Given via catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo head and neck CT scans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chart Abstraction
Description: Ancillary studies
Study: NCT05129111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL VIBRATION OF THE PAROTID GLANDS
Description: The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PHYSICAL VIBRATION OF THE PAROTID GLANDS
Description: The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation
Study: NCT06030154

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity Therapy
Description: Amplification of Positivity Therapy
Study: NCT05690152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeSimplify web-browser-based visual field test
Description: All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
Study: NCT06030154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys and Interviews
Description: Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveys and Interviews
Description: Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
Study: NCT04839185

Intervention type: DRUG
Group type: OTHER
Intervention: Ferumoxytol infusion
Description: Ferumoxytol will be administered intravenously, by infusion, over 30 minutes. It will be used a contrast agent for MRI imaging to detect placental lesions in fetal growth restriction.~Dose will be 255 mg in 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Ferumoxytol/Feraheme will be administered only once, in one infusion of 255 mg to each subject.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI scan
Description: The MRI scanning procedure will last for approximately 60 minutes.
Study: NCT05393544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally assisted peer recovery coach
Description: The certified peer recovery coach utilized an existing care coordination smartphone app to provide support to the patient during and after an inpatient detoxification treatment for alcohol use disorder. The coach utilized the telephone or text messages to send daily motivational messages, remind about upcoming appointments, and checked-in if responses were concerning. Follow-up by the coach continued for 30 days.
Study: NCT05362825

Intervention type: DRUG
Intervention: Neo-adjuvant Chemotherapy FOLFOXIRI Regimen
Description: Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.

Intervention type: PROCEDURE
Intervention: synchronous resection surgery
Description: Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
Study: NCT05070845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06835375
Description: CXCR5 inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06835375
Description: CXCR5 inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06835375
Description: CXCR5 inhibitor
Study: NCT05448053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ilizarov
Description: Ilizarov fixation in open type III pediatric and adolescent tibial shaft fractures
Study: NCT06216769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Those in the non-interrupted anticoagulation group, anticoagulation is continued regardless of atrial fibrillation recurrence.~Those in the pill-in-the POCKET anticoagulation group will receive direct oral anticoagulation only if they have atrial fibrillation recur over 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Those in the non-interrupted anticoagulation group, anticoagulation is continued regardless of atrial fibrillation recurrence.~Those in the pill-in-the POCKET anticoagulation group will receive direct oral anticoagulation only if they have atrial fibrillation recur over 6 hours.
Study: NCT06129006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydrodilatation with steroid in group A versus hyalase in group B
Description: Hydrodilatation technique:~the ultrasound transducer will be placed on the posterior surface of the shoulder in the longitudinal plane to identify the posterior glenohumeral joint, bony glenoid, humeral head, and infraspinatus muscle.Then, after sterilizing the area to be injected, the needle will be advanced to the target point between the humeral head cartilage and the infraspinatus tendon using the ultrasound-guided in-plane technique.To ensure the injection into the glenohumeral joint, the Doppler mode will be used to confirm the widening of the space between the humeral cartilage and the innermost synovial line of the infraspinatus muscle by the injected solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydrodilatation with steroid in group A versus hyalase in group B
Description: Hydrodilatation technique:~the ultrasound transducer will be placed on the posterior surface of the shoulder in the longitudinal plane to identify the posterior glenohumeral joint, bony glenoid, humeral head, and infraspinatus muscle.Then, after sterilizing the area to be injected, the needle will be advanced to the target point between the humeral head cartilage and the infraspinatus tendon using the ultrasound-guided in-plane technique.To ensure the injection into the glenohumeral joint, the Doppler mode will be used to confirm the widening of the space between the humeral cartilage and the innermost synovial line of the infraspinatus muscle by the injected solution.
Study: NCT06166251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low ıntensity aerobic exercise
Description: The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low ıntensity aerobic exercise
Description: The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate ıntensity aerobic exercise
Description: The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate ıntensity aerobic exercise
Description: The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
Study: NCT05746000

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Group (IG)
Description: Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group (CG)
Description: Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
Study: NCT06282302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group control
Description: Group control The control session will consist of keeping the volunteer sitting in a calm, air-conditioned environment for 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Exercise
Description: The intervention with isometric exercise for the lower limbs, the volunteers will start in a vertical position, with shoulders and hips in contact with the wall, feet parallel and shoulder-width apart and hands at the sides of the body. Then (second phase), the volunteers, maintaining contact with the wall, squatted and advanced their feet in the desired position until the knee joint angle reached the previously determined value. The third phase referred directly to the isometric effort of the isometric exercise session. For the isometric wall squat exercise session, volunteers will be asked to perform 4 repetitions of 2 minutes, with a 2-minute rest interval in a seated position for adequate rest between each repetition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Volunteers will perform 50 minutes of horizontal exercise cycling (brand: pro-user), continuously and at moderate intensity (50% to 60% of HR reserve).
Study: NCT05371795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort Marker 2.0
Description: The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lancets
Description: The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
Study: NCT04752228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Philadelphia ACE Survey
Description: The Philadelphia ACE survey assesses the three major domains featured within the original ACE Study Questionnaire developed by Felitti et al. (abuse, neglect, and family dysfunction), in addition to five community-level stressors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Assessment
Description: The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle Assessment
Description: The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.